Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in
patients with sensitive EGFR mutations advanced non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd